Internal Medicine, Hematology & Oncology · Scottsdale, AZ
NPI
1619101771
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8880 E Desert Cove Ave
Scottsdale, AZ, 85260
Phone (480) 314-6670
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.6M
173,269 services
Medicare patients, 2024
803
Average age 76
Drug cost, 2024
$4.5M
1,376 prescriptions
Company payments, 2025
$2,564
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Leslie Klein was code J1439 (injection, ferric carboxymaltose, 1 mg), 44,250 times for 42 patients. In total Leslie Klein billed 173,269 services in 132 codes, and Medicare paid $2.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-11-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 44,250 | 42 | $0.87 | $39K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 12,775 | 125 | $0.10 | $1,277 |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 10,680 | 11 | $0.22 | $2,359 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,600 | 17 | $44.65 | $339K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 7,345 | 16 | $2.30 | $17K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,150 | 16 | $0.11 | $688 |
| J0897 Injection, denosumab, 1 mg | Office | 5,820 | 17 | $20.53 | $119K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,514 | 13 | $0.08 | $281 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,820 | 19 | $37.25 | $105K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,340 | 42 | $0.09 | $122 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 960 | 36 | $0.75 | $717 |
| 99213 Office E&M - Established | Office | 641 | 324 | $62.72 | $40K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 475 | 11 | $0.23 | $110 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 416 | 22 | $0.07 | $31.05 |
| J9190 Injection, fluorouracil, 500 mg | Office | 342 | 11 | $2.34 | $799 |
By year: 2022 $2.5M for 157,178 services; 2023 $2.1M for 154,355 services; 2024 $2.6M for 173,269 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82565 Clinical Chemistry | 16 | 16 | $5.02 | $80.32 |
Medicare prescription drug claims, 2024
In 2024, the drug Leslie Klein prescribed most often to Medicare patients was Anastrozole, with 191 prescriptions and refills. In total Leslie Klein wrote 1,376 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 191 | 507 | 57 | $2,802 |
| Gabapentin Generic | 78 | 95 | 21 | $1,103 |
| Alendronate Sodium Generic | 77 | 202 | 21 | $641 |
| Eliquis Apixaban | 73 | 109 | 17 | $63K |
| Acyclovir Generic | 66 | 95 | Under 11 | $599 |
| Olanzapine Generic | 56 | 62 | 12 | $552 |
| Xarelto Rivaroxaban | 55 | 105 | 15 | $64K |
| Dexamethasone Generic | 50 | 62 | 24 | $622 |
| Revlimid Lenalidomide | 46 | 46 | Under 11 | $863K |
| Ondansetron Odt Ondansetron | 44 | 50 | 30 | $952 |
| Hydroxyurea Generic | 41 | 80 | 11 | $1,425 |
| Lenalidomide Generic | 41 | 41 | Under 11 | $555K |
| Folic Acid Generic | 32 | 78 | 11 | $242 |
| Tamoxifen Citrate Generic | 31 | 75 | Under 11 | $555 |
| Letrozole Generic | 28 | 84 | Under 11 | $857 |
Brand drugs: 360 claims; generic drugs: 1,016 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Leslie Klein $2,564 ($2,564 in general payments such as food, travel and fees) from 35 companies. The largest payer was Abbvie Inc. with $218.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 11 | $218 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $193 |
| Merck Sharp & Dohme LLC MRK | 6 | $168 |
| Pfizer Inc. PFE | 7 | $163 |
| Array Biopharma Inc PFE | 9 | $161 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $155 |
| Daiichi Sankyo Inc. 4568.T | 5 | $141 |
| Janssen Biotech, Inc. JNJ | 5 | $110 |
| Incyte Corporation INCY | 4 | $102 |
| GlaxoSmithKline, LLC. GSK | 4 | $88.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.